Stemcell 73082 Dasatinib
Product Overview
Dasatinib is a potent, ATP-competitive tyrosine kinase inhibitor. It is specific for SRC/ABL kinases, for example, ABL, SRC, LCK, and YES with IC₅₀ values of < 1.0, 0.5, 0.4 and 0.5 nM, respectively, and also demonstrates activity against KIT with an IC₅₀ = 5.0 nM (Lombardo et al.; Davis et al.) Dasatinib is a second-generation inhibitor of the oncogenic tyrosine kinase BCR-ABL with 325-fold more potency than imatinib, and is also able to inhibit imatinib-resistant BCR-ABL mutants (Tokarski et al.). It also inhibits a large number of other kinases (76 of 148 kinases tested) when screened at 10 μM (Carter et al.).
CANCER RESEARCH
· Inhibits proliferation in cell lines derived from chronic myeloid leukemia (CML), prostate, breast, and colon tumors (Lombardo et al.).
· Inhibits proliferation of cells with imatinib-resistant BCR-ABL mutations (Shah et al.).
· Inhibits tumor growth and development of lymph node metastases in orthotopic nude mouse models of prostate cancer (Park et al.).
· Induces cell-cycle arrest and apoptosis and decreases growth in thyroid cancer cells (Chan et al.).
· Inhibits production of extracellular matrix proteins in dermal fibroblasts and prevents development of bleomycin-challenge-induced fibrosis in mice (Distler & Distler; Akhmetshina et al.).
CAS Number:302962-49-8
Alternative Names:BMS 354825, Sprycel
Chemical Formula:C₂₂H₂₆ClN₇O₂S
Molecular Weight:488.0 g/mol
Purity:≥ 98%
Pathway:酪氨酸激酶
Target:ABL; LCK; SRC
Related products
Description | Catalog # | Format |
Dasatinib, 100 mg | 73084 | 100 mg |
Dasatinib, 10 mg | 73082 | 10 mg |
DAPT, 5 mg | 72082 | 5 mg |
DAPI (HCl), 10mg | 75004 | 10 mg |
Dabrafenib, 50 mg | 73074 | 50 mg |
Dabrafenib, 10 mg | 73072 | 10 mg |
Uante,您的科研物资战略合作伙伴!
重庆市寰宇安泰生物科技有限公司